NICO BrainPath is claimed to be the first and only technology that offers minimally disruptive access. Credit: Raman Oza from Pixabay.

NICO has announced that its complete technology solution, comprising BrainPath and Myriad, has gotten initial positive results in the ENRICH study (early minimally-invasive removal of intracerebral haemorrhage (ICH)) compared to standard of care (SOC).

NICO BrainPath is claimed to be the first and only technology that offers minimally-disruptive access using a trans-sulcal, parafascicular surgical approach.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NICO Myriad enables surgeons to achieve automated, non-ablative removal of tumours and evacuation of haemorrhages. At the same time, the company’s Automated Preservation System is used for the intra-operative automated collection and biological preservation of tissue while minimising degradation.

The study’s objective was to evaluate the safety, effectiveness and economic outcomes of early minimally invasive parafascicular surgery (MIPS) utilising NICO’s complete technology solution in comparison to standard care for ICH or haemorrhagic stroke.

The SOC is medical management (MM) based on the guidelines of the American Heart Association/American Stroke Association guidelines.

A randomised and multi-centre clinical trial evaluated the standardised early MIPS approach in 300 patients suffering from spontaneous haemorrhagic stroke.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial comprised 208 patients with a haemorrhage in the lobar region and 92 patients who had experienced it in the anterior basal ganglia area.

NICO president and CEO Jim Pearson said: “The results of the ENRICH trial are revolutionary and represent an advancement for improving outcomes for the millions of people who suffer haemorrhagic strokes.”

The utility-weighted modified Rankin Scale (UWmRS) was used to assess functional outcomes in the ENRICH trial at the end of six months.

The mean UWmRS score in the MIPS group was 0.458 compared to 0.374 in the MM group. The observed difference indicated that the treatment is superior to SOC with a 98.1% posterior probability of superiority.